Mereo BioPharma Group plc
corporate_fare Company Profile
Mereo BioPharma Group plc (NASDAQ:MREO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 16 items for MREO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 16 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for MREO spans 8-K, 10-Q, PRE 14A, 10-K.
Recent high-impact activity:
- Mereo Q3 Loss Narrows to $5.9M; $26.1M Cash Funds Operations Into Late 2027
- Mereo BioPharma Gets Second Nasdaq Delisting Notice, Compliance Deadline Extended to Feb 2027
- Mereo Narrows Q2 Loss to $7M, Extends Cash Runway into Late 2027, and Partners Alvelestat with Sentynl for Up to $475M
- Mereo BioPharma Q2 2026: Cash Runway Extended to Late 2027, Setrusumab Regulatory Path Takes Shape
- Mereo BioPharma Partners with Sentynl for Alvelestat in AATD-LD — Up to $475M in Milestones Plus Royalties
Financial Snapshot
Short Interest & Short Volume
7.01 days to coverFINRA reported short interest of 3,348,510 shares in MREO as of the October 30, 2026 settlement, a 3.7% increase from the prior period — about 7.0 days to cover at its recent average daily volume. On November 20, 2026, 40.2% of MREO volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.